An observational study for Xin-Guan-1 formula in the treatment of novel coronavirus pneumonia (COVID-19)
Phase 1
Not yet recruiting
- Conditions
- novel coronavirus pneumonia (COVID-19)
- Registration Number
- ITMCTR2000002980
- Lead Sponsor
- Guangdong Provincial Hospital of Chinese Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Patients who meet the diagnostic criteria of Hubei Province pneumonia infected by novel coronavirus(2019-nCoV), and clinical classification of mild, moderate and severe were included.
Exclusion Criteria
?Allergic constitution, ie, allergic history to 2 or more kinds of medicine or food, or to the medicines of our study.
?Patients who do not agree with taking traditional Chinese medicine.
Study & Design
- Study Type
- Observational study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Time to remission/disappearance of primary symptoms: defined as the number of days when the three main symptoms of fever, cough, and shortness of breath are all relieved / disappeared;Completely antipyretic time: completely antipyretic was defined as the body temperature return to normal for over 24 hours.;
- Secondary Outcome Measures
Name Time Method Routine blood test;Time to 2019-nCoV RT-PCR negativity: defined as the last test time for two consecutive negative respiratory viral nucleic acid tests (sampling interval of at least 1 day);Blood oxygen saturation;Length of hospital stay: defined as the time from the start of isolation treatment for n-CoV pneumonia to the time when the isolation is released from the hospital or transferred to the appropriate department for other diseases according to the condition;Blood gas analysis;C-reactive protein;Incidence of medical complications during hospitalization: defined as medical complications during pneumonia isolation hospitalization due to novel coronavirus infection, including combined bacterial infections, exacerbation of underlying diseases, etc;Conversion of severe and critical cases: defined as the number of severe and critical cases that occurred after the study was included and the intervention was initiated;Chest imaging;Liver and renal function;